Hilo, previously known as Aktiia, has raised $42m in an oversubscribed Series B funding round, co-led by Earlybird Health and Wellington Partners, to advance its blood pressure intelligence platform.
New investors, including Kfund and naturalX Health Ventures, alongside existing investors such as Khosla Ventures and Molten Ventures, participated in the funding round.
The funding will support Hilo’s continued product innovation, expansion into new markets, and the development of its blood pressure intelligence platform for enterprise use cases.
The company aims to make cuffless, clinically validated blood pressure monitoring universally accessible and effortless through its rebranding from Aktiia to Hilo.
A part of the investment, which brings Hilo’s total financing to over $100m, Earlybird Health principal Christoph Massner will be appointed as a member of Hilo’s Board of Directors.
Christoph Massner said: “By building on a validated medical device platform and an intuitive, user-friendly design, they bridge the gap between clinical reliability and everyday usability.
“It’s a rare combination that empowers users to take meaningful control of their health with minimal effort. This is especially critical given the enormous medical need: uncontrolled high blood pressure remains one of the leading risk factors for death worldwide.”
Wellington Partners managing partner Johannes Fischer said: “We are excited to co-lead this financing and to be backing Hilo’s innovative technology, which provides groundbreaking advancements to the billions of people with elevated blood pressure today.
“We believe that real-time and continuous access to blood pressure information will change the way we think about the monitoring and management of one of the most common risk factors to human health.”
Hilo has secured CE marking for its mobile phone camera blood pressure monitoring technology and has obtained regulatory approvals in Australia, Canada, and Saudi Arabia.
The company also reported a 76% compounded annual revenue growth and completed a pivotal clinical trial ahead of its US FDA application.
Hilo has sold over 120,000 devices, establishing itself in the health tech sector.
The company developed a foundational Machine Learning model for blood pressure.
It was trained on tens of billions of optical signals from real-world users and refined with hundreds of millions of calibration points.
Hilo CEO Raghav Gupta said: “This funding round is a testament to the confidence our investors have in Hilo’s groundbreaking technology and our mission to manage the world’s blood pressure via more frequent, convenient and accurate measurements.
“With billions worldwide suffering from hypertension, only 20% of whom are in control of their blood pressure, the need for innovative, accessible blood pressure monitoring solutions has never been greater.
“Our rebrand to Hilo represents more than just a name change, it’s a commitment to empowering users around the world with smarter tools to optimise their health.”
